| 摘要: |
| 目的 探讨苹果酸法米替尼治疗转移性肾细胞癌的临床疗效。 方法 2011年10月至2015年6月在第二军医大学长海医院接受法米替尼治疗并完成随访的转移性肾细胞癌9例,法米替尼25 mg/d为起始剂量治疗,每日早餐前口服。42 d为1个周期,观察肿瘤疗效及不良反应。 结果 9例患者服药期间第3周期末获部分缓解6例、疾病稳定2例、疾病进展1例,客观缓解率为66.7%(6/9)。中位随访时间29个月(15~40个月),中位无进展生存时间16.5个月(4.5~38.0个月)。不良反应以蛋白尿为主,其余与舒尼替尼相似。6例在治疗过程中因不良反应需减量或暂停服药,2例因反复不可耐受的蛋白尿终止治疗。 结论 法米替尼对转移性肾细胞癌患者具有良好的治疗效果,是一种不良反应可控的分子靶向药物,具有一定的临床应用前景。 |
| 关键词: 靶向疗法 法米替尼 肾细胞癌 肿瘤转移 治疗结果 |
| DOI：10.3724/SP.J.1008.2015.01348 |
| 投稿时间：2015-10-13修订日期：2015-11-18 |
| 基金项目:上海市医学领军人才项目(2013046),上海市科技人才计划项目(13XD1400100),国家自然科学基金面上项目(81272817,81172447),国家科技部"重大新药创制"科技重大专项(2012ZX09303011002). |
|
| Clinical efficacy of famitinib malate for treatment of metastatic renal cell carcinoma-a report of 9 cases |
| LIU Bing1Δ,WANG Yang2Δ,LV Chen2,YE Hua-mao2,SUN Ying-hao2,WANG Lin-hui1* |
(1. Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China;
2. Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
△Co-first authors.
*Corresponding author.) |
| Abstract: |
| Objective To study the clinical effect of famitinib malate for treatment of metastatic renal cell carcinoma (mRCC). Methods Nine mRCC patients treated with famitinib malate in our center completed their follow-up from October 2011 to June 2015. The patients received famitinib malate at an initial dose of 25 mg, which was given orally before breakfast once a day. One cycle consisted of 42 days. The antitumor efficacy and the adverse event (AE) were observed. Results After treatment with famitinib for 3 cycles, the objective response rate (ORR) reached 66.7% (6/9) for the patients, with partial remission (PR) found in 6 patients, stable disease (SD) in 2 patients and progressive disease (PD) in 1.The median follow-up time was 29 months (15-40 months) in our study and the median progression free survival (PFS) was 16.5 months (4.5-38.0 months). The most common treatment-related AE of famitinib malate was proteinura, and other AEs were similar to those of sunitinib. Six patients had reduction and interruption as appropriate due to AEs, and 2 patients stopped the treatment due to intolerable proteinuria. Conclusion Famitinib malate has a good antitumor activity upon mRCC, and its adverse reaction is controllable, making it a promising molecule-targeted drug for clinical application. |
| Key words: target therapy famitinib renal cell carcinoma neoplasm metastasis outcome |
